PHASE I STUDY OF INTRAPERITONEAL RADIOIMMUNOTHERAPY WITH 131I-8H9 FOR PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMORS AND OTHER SOLID TUMORS INVOLVING THE PERITONEUM.
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2018
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications Peritoneal cancer; Soft tissue sarcoma
- Focus Adverse reactions
- 02 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
- 02 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.
- 26 Jan 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov.